Immunostimulant

An immunostimulatory and immunostimulatory technology, applied in the field of immunostimulants, can solve the problems of no research, changes, unknown adsorption capacity of purified tuberculin, etc., and achieve the effect of preventing recurrence or metastasis

Inactive Publication Date: 2019-04-26
CELL MEDICINE
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the case of making albumin an insoluble solid by denaturing and coagulating serum albumin at the molecular level and treating it with a protein cross-linking agent, it has not been known whether it has sufficient adsorption capacity for purified tuberculin
In addition, no studies have been conducted on the stimulation of antigen-presenting cells caused by purified tuberculin adsorbed on such albumin-insoluble solids. (or serum) protein is made into insoluble solid, and immunostimulatory substances other than purified tuberculin are loaded on it, and whether the stimulation of immunocompetent cells is changed has not been studied before.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunostimulant
  • Immunostimulant
  • Immunostimulant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0124] Hereinafter, the present invention will be described in more detail by way of examples, but the scope of the present invention is not limited to the following examples.

[0125] The terms and concepts in the present invention are based on the meanings of the terms commonly used in the art, and the techniques used in order to implement the present invention can be easily and accurately understood by those skilled in the art based on well-known documents, etc. implemented. In addition, various analyses etc. were performed using the methods described in the used analytical instruments, reagents, operating instructions of the kits, catalogues, and the like.

[0126] [Table 1]

[0127] List of acronyms

[0128]

[0129]

example 1

[0130] Example 1: Preparation of Carrier Containing Denatured Coagulated Solid Plasma, and Stimulation Effect of Antigen-presenting Cells Using Undenatured Hemoglobin Adsorption Complex or Undenatured Myoglobin Adsorption Complex

[0131] It is known that if the human macrophage-like cell line THP-1 is induced to differentiate under the culture of Phorbol 12-Myristate 13-Acetate (phorbol 12-myristate 13-acetate, PMA), not only It exhibits phagocytic ability (Non-Patent Document 18), and also acquires antigen-presenting ability to become antigen-presenting cells (Non-Patent Document 19). Furthermore, when the cells are pretreated with human interferon gamma (IFNg) as a cytokine, the antigen-presenting ability to T cells is enhanced (Non-Patent Document 20). Differentiated and phagocytosed THP-1 cells produce TNFα (Non-Patent Document 21). It is known that the production of TNFα shows the activation of macrophages (or antigen-presenting cells), and the activation of macrophages (...

example 2

[0148] Example 2: Stimulatory effect of antigen-presenting cells by denaturation and coagulation of solidified albumin / hemoglobin complex

[0149] In Example 1, it was shown that the substance in which undenatured hemoglobin is adsorbed on the denatured coagulated solid plasma carrier has a stimulating effect on antigen-presenting cells, but albumin, which is a representative example of serum proteins, and erythrocyte-derived hemoglobin were mixed in advance. , to study the stimulating activity of antigen-presenting cells when the mixture was denatured, coagulated and solidified.

[0150] (1) Preparation method of sample for bioassay

[0151] For a commercially available biological preparation standard, human serum albumin (manufactured by the Institute of Chemistry and Serotherapy, donated blood albumin 25 "Kaxueken", hereinafter referred to as "25% HSA") was prepared at the ratio shown below A liquid obtained by mixing human hemoglobin (manufactured by SIGMA, H7379-5G, diss...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A complex usable as a highly safe immunostimulant, the complex comprising a carrier which contians a plasma-derived protein or serum-derived protein having been solidified by denaturing and coagulating and a protein which is carried by the carrier and has a peroxidase-like activity, being capable of strongly stimulating an antigen-presenting cell and thus highly efficacious, and yet having a reduced toxicity to living organisms.

Description

technical field [0001] The present invention relates to immunostimulants. More specifically, it relates to an immunostimulatory agent containing a plasma-derived protein or a serum-derived protein solidified by denaturation and coagulation as a carrier. Background technique [0002] Immunity is generally known to have two types of natural immunity and acquired immunity. Substances that cause an inflammatory response in an organism mainly stimulate natural immunity, triggering an inflammatory response between minutes and days. Immunity is then induced, and a specific response is elicited to the substance that becomes the antigen. This reaction mainly includes a liquid immune response (production of antibodies) using B cells, and a cellular immune response (removal of damage from abnormal cells) using T cells. Vaccines give an antigen to an organism and are used to stimulate immunity to prevent (and, depending on the case, treat) diseases such as infectious diseases. In ad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K31/713A61K38/19A61K38/20A61K38/21A61K38/42A61K38/44A61K39/00A61K39/04A61K39/395A61K47/64A61P35/00A61P35/04A61P37/04
CPCA61K38/19A61K38/20A61K38/21A61K38/42A61K38/44A61K39/00A61K39/04A61K39/39A61K39/395A61K31/713A61K47/64A61P37/04A61P35/04A61P35/00A61K38/164A61K39/0011A61K39/385A61K45/06A61K2039/6031A61K2039/55566A61K2039/585A61K2039/57A61K2039/55516A61K2039/55583A61K2039/55533A61K47/62
Inventor 大野忠夫
Owner CELL MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap